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Abstract
Background
Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and
has a high risk of distant metastasis at every disease stage. We aimed to characterize the
genomic landscape of LUAD and identify mutation signatures associated with tumor
progression.
Methods and Findings
We performed an integrative genomic analysis, incorporating whole exome sequencing
(WES), determination of DNA copy number and DNA methylation, and transcriptome
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sequencing for 101 LUAD samples from the Environment And Genetics in Lung cancer Eti-
ology (EAGLE) study. We detected driver genes by testing whether the nonsynonymous
mutation rate was significantly higher than the background mutation rate and replicated our
findings in public datasets with 724 samples. We performed subclonality analysis for muta-
tions based on mutant allele data and copy number alteration data. We also tested the
association between mutation signatures and clinical outcomes, including distant metasta-
sis, survival, and tumor grade. We identified and replicated two novel candidate driver
genes, POU class 4 homeobox 2 (POU4F2) (mutated in 9 [8.9%] samples) and ZKSCAN1
(mutated in 6 [5.9%] samples), and characterized their major deleterious mutations.
ZKSCAN1 was part of a mutually exclusive gene set that included the RTK/RAS/RAF path-
way genes BRAF, EGFR, KRAS, MET, and NF1, indicating an important driver role for this
gene. Moreover, we observed strong associations between methylation in specific genomic
regions and somatic mutation patterns. In the tumor evolution analysis, four driver genes
had a significantly lower fraction of subclonal mutations (FSM), including TP53 (p = 0.007),
KEAP1 (p = 0.012), STK11 (p = 0.0076), and EGFR (p = 0.0078), suggesting a tumor initia-
tion role for these genes. Subclonal mutations were significantly enriched in APOBEC-
related signatures (p < 2.5×10−50). The total number of somatic mutations (p = 0.0039) and
the fraction of transitions (p = 5.5×10−4) were associated with increased risk of distant
metastasis. Our study’s limitations include a small number of LUAD patients for subgroup
analyses and a single-sample design for investigation of subclonality.
Conclusions
These data provide a genomic characterization of LUAD pathogenesis and progression.
The distinct clonal and subclonal mutation signatures suggest possible diverse carcinogen-
esis pathways for endogenous and exogenous exposures, and may serve as a foundation
for more effective treatments for this lethal disease. LUAD’s high heterogeneity empha-
sizes the need to further study this tumor type and to associate genomic findings with clini-
cal outcomes.
Author Summary
Why Was This Study Done?
• Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer
and causes more than half a million deaths worldwide annually.
• Genomic studies of LUAD can shed light on tumor initiation and progression and iden-
tify potential targets for treatment.
What Did the Researchers Do and Find?
• We performed an integrative genomic analysis, incorporatingwhole exome sequencing
(WES), DNA copy number and DNA methylation determination, and transcriptome
Integrative Genomic Analysis of Lung Adenocarcinoma
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sequencing in 101 LUAD samples. We replicated major findings using public genomic
resources and combined all existing genomic data for an overall analysis of 825 LUAD
samples.
• We identified two novel driver genes and characterized the driver events and types of
mutations that have a stronger role in tumor initiation versus tumor progression.
• We found strong associations betweenDNA methylation and somatic mutation patterns.
• The total number of somatic mutations and the fraction of C!T transitions were associ-
ated with increased risk of distant metastasis.
What Do These Findings Mean?
• We characterized LUAD genomic architecture and linkedmajor genomic features with
clinical outcomes.
• Tobacco smoking-related mutations appear to have a stronger role in tumor initiation,
while mutations associated with endogenous processes are more prominent at a later
stage of tumor development and are associated with tumor progression.
• Our findings highlight the complexity and heterogeneity of LUAD. In addition to new
driver genes, we found some tumors with no exonic mutations in known lung cancer
driver genes. This suggests that there are further drivers (genetic or epigenetic) to be
identified, and larger numbers of samples need to be studied to fully capture LUAD
genomic characteristics.
Introduction
Lung cancer is the major cause of cancer mortality, causing approximately 1.38 million deaths
worldwide annually [1]. Lung adenocarcinoma (LUAD) is the most common histologic sub-
type and accounts for more than 40% of lung cancer incidence. The absolute risk of distant
metastasis in LUAD exceeds that of local recurrence at every disease stage, highlighting the sys-
temic threat of the disease [2].
Multiple studies have been performed to characterize the genomes and transcriptomes of
LUAD tumors. Array-based copy number aberration (CNA) studies [3,4] have identified
important amplified genes, includingNKX2-1,TERT, EGFR, andMET, and deleted genes,
including CDKN2A. Targeted sequencing of protein-coding genes [5,6] and whole-exome
sequencing (WES) [4,7–9] of tumor/normal or tumor/blood sample pairs have identifiedmore
than 20 mutated genes that showed positive selection in LUAD. Moreover, transcriptome
sequencing has discovered recurrent gene fusions, including EML4-ALK [10], KIF5B-RET
[11,12], and ROS1 fusions [13]. These studies nominated driver genes and provided targets for
treatment. For patients with EGFRmutations or ALK fusions, targeted kinase inhibitors have
superior efficacy compared with the traditional chemotherapy [14].
Althoughmany genes have been identified as potential drivers and targets for therapy, a
large fraction of LUAD patients do not carrymutations in the set of most frequently mutated
genes, suggesting substantial heterogeneity in the genomic drivers of LUAD. This observation
highlights the need to sequence further LUAD samples to identify additional driver genes and
targets for treatment.
Integrative Genomic Analysis of Lung Adenocarcinoma
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In the current study, we sequenced the exome of tumor/blood sample pairs of 101 LUAD
patients and the transcriptome of 80 LUAD tumor tissue samples from the Environment And
Genetics in Lung cancer Etiology (EAGLE) study [15], in which a cohort of patients with
LUAD were followed up for several years and comprehensive data on demographic, behavioral,
and clinical characteristics were collected.Most patients were heavy smokers and were diag-
nosed at an early disease stage.
The study has several aims: to identify novel driver genes and gene fusions, to investigate
the relationship betweenDNA methylation and somatic mutation signatures, to perform sub-
clonality analysis, and to investigate the association of genomic features with exposures (e.g.,
tobacco smoking) and clinical characteristics (including survival, distant metastasis, tumor
grade, and chronic obstructive pulmonary disease [COPD]).
Methods and Materials
Samples
The study protocol was approved by the institutional review board of the United States National
Cancer Institute and the involved institutions in Italy. Informed consent was obtained for all sub-
jects prior to study participation.We assayed 101 fresh-frozen stage I to IIIA lung adenocarci-
noma tumor tissue samples from the EAGLE study [15], a large population-based, case–control
study conducted in the Lombardy region of Italy betweenApril 2002 and February 2005. All
subjects were of Italian nationality between the ages of 35 and 79 years, official residents of the
catchment area, and with no severe disease that could impede participation. Cases were newly
diagnosedprimary cancers, verified by tissue pathology. Lung tissue samples were snap-frozen in
liquid nitrogen within 20 min of surgical resection. Surgeons and pathologists were present
together in the surgery room at the time of resection and sample collection to ensure correct sam-
pling of tissue from the tumor, adjacent lung tissue, and distant noninvolved lung tissue. The pre-
cise site of tissue sampling was indicated on a lung drawing and classified by the pathologists. For
the current study, we selected 101 samples based on the histological characteristics (pure adeno-
carcinoma, not mixed types or undifferentiated cases), the presence of at least 50% tumor nuclei
and less than 20% necrosis on histological review of the samples, and whether there was sufficient
amount and quality of DNA and RNA needed for all the analyses.
All subjects in the EAGLE study were followed up in the same rigorous way. Detailed infor-
mation on tumor characteristics, recurrence, treatment, and follow-up data were recovered
from patients’ medical records at the end of the follow-up. After study completion, we identi-
fied follow-up visits and hospital admissions by linkage with the regionwide Regional Health
Authority database of hospital admissions. Recurrence history was ascertained through
December 31, 2010. Detailed clinical information was retrieved for each hospitalization and/or
outpatient visit and reviewed by the clinical team that coded local recurrence and metastases
[2]. The definition of local or distant recurrences followed the lung cancer staging as defined by
the American Joint Committee on Cancer (AJCC), 7th Edition.
Whole Exome Sequencing and Mutation Calling
Exome capture was performed using Agilent SureSelectHuman All Exon V4, and whole
exomes were sequenced on Illumina HiSeq 2000, both from Oxford Gene Technology (OGT).
For paired-end reads from tumor and matched germline samples, we performed quality-based
trimming and filtering by Trimmomatic (version 0.30). In this step, we removed the adapter
and other Illumina-specific sequences from the reads. We removed the leading and trailing
bases in a read if the quality scores were below 12. We also scanned from the 50 end of the read
with a 4-base wide sliding window and removed the 30 end of the read when the average quality
Integrative Genomic Analysis of Lung Adenocarcinoma
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per base dropped below 15. We removed the reads below 36 bases after trimming. The
sequence data were then aligned to the hg19 version of the human reference using Novoalign
(version 3.00.05) and deduplicated by Picard (version 1.83). Local realignment around sus-
pected sites of indels were performed using Genome Analysis Toolkit (GATK) IndelRealigner
(version 2.8.1). These mapped sequence reads were used for mutation calling. Somatic single
nucleotide variants (SNV) were identified using MuTect [16] (version 1.1.4) with default
parameters. Indels were identified using GATK Indelocator. We identifiedAPOBEC-mediated
mutations as cytosine-to-thymine and cytosine-to-guanine substitutions in the TCWmotifs
(withW being either A or T) [17].
Functional Annotation of Mutations Identified in Novel Driver Genes
Sequence variations were mapped to the corresponding genomic coordinates and inspected
using the genome browsers of Ensembl (www.ensembl.org) and NCBI (www.ncbi.nlm.nih.
gov). Protein sequence based information was extracted from the UniProt database (www.
uniprot.org). Prosite domain based analysis was carried out using the Prosite database (http://
prosite.expasy.org/). The 3-D structural coordinates for the relevant proteins were downloaded
from the RCSB-PDB database (www.rcsb.org). For the 3-D fold–based analysis, protein models
were built using the Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index)and
I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER) servers. Impact analysis predic-
tions were carried out using MutationTaster (http://www.mutationtaster.org/), SIFT (http://
sift.bii.a-star.edu.sg/), Provean (http://provean.jcvi.org/index.php), AVIA: Annotation, Visual-
ization, and Impact Analysis (https://avia-abcc.ncifcrf.gov/apps/site/index; ver 2.0), and the
Variant Effect Predictor (VEP) from Ensembl. The splice site variants were analyzed using
Human Splicing Finder (vers 2.4.1 and 3.0). The Human Genome Variation Society (www.
hgvs.org) was consulted for reporting variations.
Transcriptome Sequencing and Gene Fusion Analysis
Transcriptome sequencing of 80 tumor samples with RIN (RNA Integrity Number) 6 was per-
formed on the IlluminaHiSeq2000/2500 platform with 100 bp paired-end reads. The remaining
21 tumor samples had RNA with poor quality or amount and were not used for this analysis.
Sequence reads were mapped by the Mapsplice algorithmwith default parameters.We used the
generic annotation file (version TCGA.hg19.June2011.gaf) to annotate genes and exons. Candi-
date gene fusion events were nominated by DeFuse [18]. The fusions were excluded if either
break point was located in intron regions or within 100 kb of the same chromosome. After filter-
ing, we selected 11 fusion events for validation. RNA extracted from patient samples was reverse
transcribedwith SuperScript III (Life technologies). Each cDNA library was subsequently ampli-
fied using fusion specific primers. Amplicons were electrophoresed and products of sizes that
were similar to what was predictedwere purified using Ampure XP (Epicentre). Purified ampli-
cons were end-repaired, barcoded, adapted and pooled, and subsequently sequenced on an Ion
Personal GenomeMachine (PGM) sequencer (Thermo Fisher Scientific). Sequence data were
uploaded to the Seven Bridges Genomics platform. FastQ sequence data were converted to BAM
file formats and fusion transcripts were detected using STAR and Chimera pipelines. Results
were filtered and analyzed using the Picard Alignment summary pipeline.
DNA Methylation Profiling and Analysis
Bisulphite treatment and Illumina InfiniumHumanMethylation450 BeadChip assays [19]
were performed to profile the fresh-frozen tumor samples in the EAGLE cohort. Rawmethyl-
ated and unmethylated intensities were background-corrected and dye-bias-equalized to
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correct for technical variation in signal between arrays. For background correction, we applied
a normal-exponential convolution, using the intensity of the Infinium I probes in the channel
opposite their design to measure nonspecific signals. Dye-bias equalization used a global scal-
ing factor computed from the ratio of the average red and green fluorescing normalization con-
trol probes. For each CpG probe in the platform, the DNA methylation level was summarized
as the fraction of signal intensity obtained from the methylated beads over the total signal
intensity. After excluding CpG probes annotated with genetic variants (single nucleotide poly-
morphisms or copy number variations), in repetitive genomic regions or on the X chromo-
some, 338,730 CpG probes remained for analysis. Each CpG probe was annotated as in CpG
island (denoted as CGI), nonCGI (including shores and shelves) or “open-sea”. Each CpG
probe was also annotated as in promoter (TSS200, TSS1500, and first exon), body, 30UTR in a
specific gene, or annotated as intergenic. A CpG probe may have multiple different annotations
depending on the transcripts used for annotation.
Copy Number Alteration Analysis
DetectingCNAs is crucial for characterizing tumor genomes and also for estimating tumor
purity and subclonality. We profiled CNAs for tumor samples using Illumina HumanOmniEx-
press SNP arrays. The majority of lung tumor genomes were disrupted by many CNAs with
complex clonality (see example in S1A Fig), which made the segmentation difficult based on
the intensity data. The B allele frequency (BAF) data for the heterozygous SNP probes provided
a cleaner segmentation for CNAs (S1A Fig). Thus, we used Nexus (http://www.biodiscovery.
com/nexus-copy-number/) to segment the cancer genome based on BAF data, followed by
manual verification. For each segment, the sequencing read ratio between the tumor DNA
sample and the matched germline DNA sample was used to determine whether it was amplifi-
cation, hemizygous deletion (CN1), homozygous deletion (CN0), loss of heterozygosity
(LOH), or copy neutral (CN2). We identified genomic regions significantly disrupted by CNAs
using GISTIC [20,21]. We estimated tumor purity and subclonality based on detected deletions
and LOH events using a Gaussian mixture model. Amplifications were excluded from the anal-
ysis because of their large amplitude variability. Details are presented in S1 Text and S1 Fig.
We note that the estimated purity may be different from the histology-basedcount of tumor
nuclei, which was manually determined and subject to human error.
Subclonality Analysis for Somatic Point Mutations
A clonal SNV is a point mutation carried by all tumor cells, while a subclonal mutation is car-
ried by a fraction of tumor cells. Previously developedmethods (e.g., [22]) determine subclon-
ality of a SNV by modeling the mutation allele fraction (MAF) and the copy number of the
locus. However, these methods assume that CNAs at the locus are clonal to simplify the prob-
lem. This assumption is expected to cause incorrect statistical inference. Here, we extend the
reportedmethod [22] to infer whether a SNV is clonal or subclonal by accounting for tumor
purity, CNA, and its subclonality (S2 Fig and S2 Text). Because of the difficulty in estimating
the absolute copy number and the subclonality for amplifications, we restricted our analysis to
mutations in normal, deleted, and LOH regions. For each gene, or a specified set of somatic
mutations, we calculated the fraction of subclonal mutations out of all somatic mutations
across patients.
Statistical Analyses
This study performed integrative genomic analysis based on a set of lung cancer patients and
had no prospective clinical protocol or analysis plan. The associations between genomic
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features (total number of somatic mutations, fractions of nine point mutation types, mutation
status of KRAS and TP53, number of fusion events) and clinical outcomes (survival, distant
metastasis, and local relapse) were assessed by the Cox regressionmodel, with significance eval-
uated by the log-rank test. The association for COPD was evaluated by logistic regression. The
association for tumor grade was evaluated using ordinal regression. All analyses were adjusted
for age, sex, stage, and, as specified, also by smoking behaviors (smoking status, cigarettes per
day, and smoking duration) in some analyses. We identified statistically significant associations
by controlling the false discovery rate (FDR)<5%. The associations betweenmutation signa-
tures and covariates (e.g., smoking behaviors) were assessed by theWilcoxon rank sum test or
Fisher’s exact test. All remaining statistical analyses were performed using the R package
(http://www.r-project.org). p-values reported in the manuscript are nominal p-values.
We evaluated the significance for selective advantage of somatic mutations for each gene
usingMutSigCV [23] and nominated significant genes by controlling FDR<5%. MutSigCV is
a program for testing whether the mutation rate of nonsynonymous mutations of a target gene
is significantly higher compared with the background silent mutation rate by combining muta-
tion data across patients. MuSigCV appropriately accounts for the heterogeneity of mutation
rate across patients and mutation types. To increase the statistical power, MutSigCV tries to iden-
tify a “bagel gene set” to better estimate the backgroundmutation rate. Here, a “bagel gene set”
for a target gene refers to the genes with similar backgroundmutation rate by matching gene
expression levels and DNA replication time. The identified novel driver genes were replicated
usingMutSigCV in the 724 samples pooling the LUAD datasets in TCGA [4] and the Broad
Institute study [7]. The mutual exclusivity for candidate driver genes was assessed usingMEGSA
[24] and mutex [25]. MEGSA aims to identify a mutually exclusive gene set (MEGS) by a likeli-
hood ratio statistic for assessingmutual exclusivity, a model selection procedure to identify the
optimal MEGS, and a permutation procedure for evaluating global significance.Mutex is a pro-
gram for identifyingMEGS by restricting gene sets with common downstream targets.
Results
Patient Characteristics
Table 1 summarizes the study subjects’ characteristics. Eight patients had neoadjuvant chemo-
therapy before surgery. The study included 7 never smokers, 42 former smokers, and 51 cur-
rent smokers. Out of the 93 ever smokers, most were heavy smokers (averaging 21.5 cigarettes
per day) for a long time (42.7 years on average). Thirty-eight patients were alive at the time of
last follow-up. As expected, stage was significantly associated with survival (p = 0.0007 for
stage II and p = 0.005 for stage IIIA, with stage I as baseline). Forty patients developed distant
metastases and 17 patients developed local relapse.
Somatic Mutations Detected in WES and Their Associations with
Smoking Characteristics
We performedWES for 101 LUAD tumor/blood sample pairs. The average WES coverage
was 107 for tumor and 58 for germline DNA samples. After excluding low quality calls, we
identified 459 indels (16 at a splice site) and 40,704 exonic point mutations, including 28,200
missense, 2,129 nonsense, 87 frameshift, 1,264 splice-site, and 10,140 silent mutations. The
average somatic mutation rate was 11.3 per megabase (Mb) in exonic regions, with 7.9 nonsy-
nonymous and 2.8 synonymous mutations on average, consistent with previously reported
rates [4,7]. The mutations are listed in S1 Table. The distribution of the point mutations is
reported in Fig 1A.
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Smoking status (ever versus never), duration, and intensity were significantly associated
with increased total number of somatic mutations (TNSM) (p = 0.007, 0.02, and 0.01, respec-
tively, Wilcoxon rank sum test). Neither disease stage nor chemotherapy history was signifi-
cantly associated with TNSM.
The mutation types were dominated by C!A and C!T signatures (Fig 1A). We investi-
gated whether the fraction of each mutation type was associated with smoking behaviors (S2
Table). Compared with never smokers, smokers had a significantly increased fraction of C!A
transversions (pCpG = 0.0007 and pnonCpG = 0.0014) and a significantly decreased fraction of
C!T transitions (pCpG = 0.0001 and pnonCpG = 0.0005). Here, pCpG and pnonCpG denote the
association p-values for mutations inside and outside of the CpG context, respectively. Number
of cigarettes per day was also significantly associated with an increased fraction of C!A trans-
versions (pCpG = 0.006 and pnonCpG = 0.004) and reduced fraction of C!T transitions (pCpG =
0.006 and pnonCpG = 0.004). Smoking duration was significantly associated with a reduced
Table 1. Distribution of demographic and clinical variables of 101 lung adenocarcinoma patients.
Age at first diagnosis (mean, range) 65.3 (44–79)
Sex
Male 83
Female 18
Smoking status
Never 7
Former 42
Current 51
Missing 1
Cigarettes per day
10 15
>10,20 48
>20,30 16
>30 12
Missing or never smokers 10
Mean (standard deviation) 21.5 (9.5)
Cigarette smoking duration
30 years 9
>30,40 35
>40,50 25
>50 years 22
Missing or never smokers 10
Mean (s.d.) 42.7 (10.7)
Tumor stage
IA 26
IB 25
IIA 21
IIB 9
IIIA 20
Chemotherapy
yes 8
no 93
Distant metastasis 40
Local recurrence 17
doi:10.1371/journal.pmed.1002162.t001
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fraction of C!T transitions within the CpG context (p = 0.004). The fraction of nucleotide
transversions was associated with smoking status (ever versus never, p = 1.7×10−4, average frac-
tion = 0.31 for never and 0.62 for ever smokers), consistent with previous reports [4,7]. We did
not detect significant differences between former and current smokers.
The fractions of APOBEC-mediatedmutations ranged from 0% to 40.7% across 101
samples (mean 10.5%), similar to the TCGA (mean = 11.1%) [17] and Broad Institute
(mean = 9.5%) [7] datasets. APOBEC-mediated mutations were depleted in nonsynonymous
mutations (p = 1.5×10−9, Fisher’s exact test): 12.6% of synonymous mutations and 10.4% of
nonsynonymous mutations were APOBEC-related. The fraction of APOBECmutations was
Fig 1. Somatic mutations of lung adenocarcinoma in EAGLE data. (A) Distribution of point somatic mutations across nine mutation types. (B) The
top panel shows the number of nonsilent mutations detected by whole-exome analysis for 101 EAGLE samples. Tumor samples were arranged from
left to right by the number of nonsilent mutations. The middle panel shows the mutations for previously reported significantly mutated genes based on
the TCGA data, reported in the TumorPortal website. The next panel shows the mutations for the three new driver genes. The bottom panels show
smoking status. The right panel shows the frequency of nonsilent mutations in EAGLE data for each driver gene. Each column represents one patient.
doi:10.1371/journal.pmed.1002162.g001
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not significantly associated with sex, age, or disease stage, nor with smoking status, intensity, or
duration.
Significantly Mutated Genes in Lung Adenocarcinoma
The TumorPortal [26] reports 37 significantlymutated genes for LUAD based on 398 TCGA
samples. A pooled analysis of 412 LUAD samples (including 231 TCGA samples and 181
Broad samples) reported 18 significantlymutated genes [4]. Among these genes, 10 were
mutated in the EAGLE sample with frequency greater than 5% (Fig 1B): TP53 (33.7%),KRAS
(30.7%),KEAP1 (23.8%), STK11 (14.9%),ARID1A (7.9%), RBM10 (8.9%), SMARCA4 (8.9%),
EGFR (8.9%),ATM (7.9%), and RBM10 (7.9%). For over 20% of the EAGLE samples, the previ-
ously identified LUAD genes had no nonsynonymous mutations.
We identified three novel significantlymutated genes: POU4F2 (p = 2.1×10−6), ZKSCAN1
(p = 4.1×10−6), and ASEF (p = 3.1×10−5) (Fig 1B) by controlling FDR<0.05. After excluding
samples from the 8 patients who had received chemotherapy, the three genes remained statisti-
cally significant (p = 5.2×10−6 for POU4F2, p = 1.9×10−5 for ZKSCAN1, and p = 3.2×10−4 for
ASEF). All mutations in the three genes were validated by Sanger sequencing.We extracted the
mutation data in these three genes from 542 TCGA LUAD samples and 182 Broad LUAD sam-
ples withWES data. S3 Table summarizes the number of synonymous and nonsynonymous
mutations in these datasets. We tested the significance of the three genes usingMutSigCV in
the 724 samples pooling the twoWES datasets. POU4F2 (p = 1.3×10−4) and ZKSCAN1
(p = 0.029) were significantlymutated, whileASEF (p = 0.46) was not. Detailed investigation
suggested that the lack of significance for ASEF was due to the high synonymous mutation rate
in the “bagel” gene set [23], which was used for estimating the background silent mutation
rate. In addition, POU4F2 and ZKSCAN1were not detected as significant driver genes in previ-
ous studies because they had a lower rate of nonsynonymous mutations.
POU4F2, also known as BRN-3B, is a member of the POU-domain transcription factor fam-
ily. Although 3-D structural data are not available for this protein, domains have been predicted
based on amino acid sequences, beginningwith amino acid 250 (aa250; POU:250–327;HOMEO-
BOX:345–404). Because of the homology between the two C-terminal conserveddomain seg-
ments, POU4F2 is considered to be part of the Pit-Oct-Unc family. Therefore, the human Oct-1
protein, with an experimentally determined 3-D conformation, can be used as the basis for
POU4F2 structure-basedanalysis. Based on the Oct1 structure, severalmutations identified in
this study are noteworthy (Fig 2): S359X (TCGA), which could lead to a nonsense-mediated
decay (NMD) or a truncated protein with the loss of most of the Homeobox domain, and R269L
(TCGA), Q276K (EAGLE), and R347L (EAGLE) variations, which couldmodify the potential
DNA binding residues, eventually disrupting protein function.Using sequence-basedanalysis,
other mutations could also be important, such as G80C (EAGLE), which is part of the glycine/
serinemotif, where the newly introduced residue cysteine has the capability to form intra- or
inter-S-S bonds that couldmodify protein structure and/or function.Moreover, histidine residue
modifications such as H173Y (TCGA) and H178Y (EAGLE) belong to the homopolymeric histi-
dine tract (Q12837:171-HHHHHHHHHHH-182) that is often associatedwith essential DNA-
and RNA-related functions [27], as well as the P135L (TCGA) and A140D (EAGLE) variants,
which are not commonly observed substitutions based on the BLOSUM62 score and are also
closely located to the previously identified histidine repeat region. Finally, the intronic variant
ENST00000281321.3:c.288+1G!A, being located in the exon–intron border, could potentially
affect normal splicing (Fig 2).
The zinc finger with Kruppel-associated box (KRAB) and SCAN (or leucine-rich region
[LeR]) domains 1 (ZKSCAN1 or ZNF139) gene encodes a transcriptional regulator protein and
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is a member of the KRAB subfamily of zinc finger proteins. Although no experimental 3-D
structural information for ZKSCAN1 is available, sequence-basedanalysis suggests that several
mutations identified in this study can disrupt ZKNSCAN1 function: e.g., Q83X (TCGA) and
E308X (EAGLE) are potential NMDmutations, and, if expressed, they could result in a trun-
cated protein with the loss of all six zinc finger domains (C2H2-1 to C2H2-6); variation
chr7:99621041G>T (TCGA) occurs as the last nucleotide in the intron 1–2, can be considered
as a splice acceptor variant, and most likely has an impact on alternative splicing; S139L
(TCGA), which adds a leucine to the end of a leucine-rich domain (prosite: PS50804); and
H395R (Broad Institute) modification,which occurs in the first zinc finger domain, possibly
disrupting the Zn2+ ion binding site (Fig 2).
The APC-stimulated guanine nucleotide exchange factor (ASEF) gene, also known as Rho
guanine nucleotide exchange factor (GEF) 4 (ARHGEF4), is a regulator of the cytoskeleton and
cell migration [28]. Detailed description of the mutations and possible biological implications
are in S3 Text.
Fig 2. Somatic mutations in three LUAD candidate driver genes (POU4F2, ZKSCAN1, and ASEF) in EAGLE, TCGA and Broad Institute
studies. The protein sequences from these three genes are schematically described using grey bars along with their respective structural and functional
domains in color-coded blocks. Each mallet represents an independent nonsilent mutation with potential functional relevance in the three studies (the
complete list of mutations is reported in S1 Table). Numbers below each sequence representation mark the total length of the transcript, the domain
ranges, and the locations of mutations.
doi:10.1371/journal.pmed.1002162.g002
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DNA Methylation and Somatic Mutation Signature
In an integrated analysis of 93 samples with both DNA methylation andWES data, we per-
formed genome-wide analysis to identify CpG probes with methylation levels associated with
somatic mutation patterns, including TNSM, fraction of transversions (FT), fraction of APO-
BEC-related mutations (FA), and fractions of the nine point mutation types. Associations were
adjusted for smoking status, age, disease stage, and sex. We identified 100 CpG probes signifi-
cantly associated with TNSM (p< 1.4×10−7, Bonferroni correction) in the EAGLE dataset. All
findings were replicated in the 393 TCGA samples with bothWES and methylation profiles at
p< 0.05 and with the same direction of association.
To increase the statistical power, we performed a meta-analysis by combining the EAGLE
and TCGA samples with bothWES and methylation data (n = 486 samples in total). This anal-
ysis identified over 1,000 CpG probes significantly associated with TNSM, FT, the fraction of
C!Amutations (both within and outside CpG regions), and the fraction of C!Tmutations
outside CpG regions (Fig 3A) (p< 1.5×10−7, Bonferroni correction).Many specific CpG
probes were associated with multiple mutation traits (CpG probe cg00042837 is presented as
an example in Fig 3B).
We investigated whether CpG probes in each annotation category were enriched for associ-
ations with each somatic point mutation trait. As an example, out of the 110,542 isolated CpG
probes (referred to as “open-sea” [29]), 12,339 (11.2%) were significantly associated with
TNSM. On average, 22,337 (6.6%) of all 338,739 CpG probes were significantly associated with
TNSM. Thus, the enrichment fold change was calculated as 11.2%/6.6% = 1.7 for CpG probes
mapping to open-sea regions. Fig 3C and 3D report the enrichment fold change. The CpG
probes mapping to open-sea and intergenic regions were strongly enriched for the associations
with almost all investigated point mutation types; the CpG probes mapping to CpG island and
gene promoter regions were strongly depleted for associations.
We calculated the fraction of positive associations of CpGs over each somatic point muta-
tion type (Fig 3E and 3F). The fractions of positive associations varied substantially across dif-
ferent mutation types and different CpG categories. For TNSM, 13.4% of associated CpG
probes mapping to open-sea regions showed positive associations, while the fractionwas
60.8% for CpG probes mapping to island regions.
Landscape of CNAs, Tumor Purity, and Clonal and Subclonal CNAs
We identified 1,931 deletions, 1,345 amplifications, and 471 LOH events with lengths greater
than 1,000,000 base pairs. On average, each sample had 19.1 deletions, 13.3 amplifications, and
4.7 LOH events. Approximately 40% of the genome was disrupted by CNAs on average. The
fractions of genomes disrupted by CNA were not significantly associated with smoking behav-
iors, disease stage, sex, or chemotherapy.
GISTIC analysis [20] restricted to large-scale deletions (>50% of chromosome arms) identi-
fied the majority of previously reported regions at FDR<0.05 [3] and new regions, including
16p and 16q. The analysis also replicated most of previously reported amplifications, including
the 1q region for large-scale amplification events and the 1q21.2, 5p15.33, 8q24.21, 12p12.1,
12q15, 14q13.3, and 19q.12 regions for focal amplification (S4 Table and S3 Fig).
Tumor purity was on average 48.5% (standard deviation = 18.9%).We estimated that 56.6%
of deletions and 90.3% of LOHs were subclonal. For each sample, we calculated the fraction of
subclonal deletions and/or LOHs and examined the association with covariates. The fractions
were nominally associated with smoking status (never versus ever, p = 0.02, Wilcoxon rank
sum test) but not with other variables such as sex, disease stage, chemotherapy, distant metas-
tasis, local recurrence, or survival.
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Clonal and Subclonal Somatic Mutations
Subclonal mutations accounted for 55.5% of all mutations that were successfully classified. The
FSMwas significantly lower for reported driver genes (FSM = 46.8%) than nondriver genes
(FSM = 55.5%) (p = 0.011, Fisher’s exact test), consistent with a recent Pan-Cancer analysis [30].
Fig 4A presents the numbers of clonal and subclonalmutations for 32 genes in LUAD withmuta-
tions in our data (other driver genes with no mutations in EAGLE samples were not included).
Four driver genes had significantly lower FSM compared with the overall FSM distribution based
on Fisher’s exact test: TP53 (p = 0.007),KEAP1 (p = 0.012), STK11 (p = 0.0076), and EGFR
(p = 0.0078). FSM significantly differed between the nine types of point mutations (Fig 4B).
APOBEC-mediatedmutations were significantly enriched in subclonal mutations (Fig 4C)
Fig 3. The associations between DNA methylation and somatic mutation signatures based on EAGLE and TCGA data. (A) The number of CpG
probes significantly associated with the TNSM and the fractions of various types of point mutations (p < 1.5×10−7, based on Bonferroni correction). (B)
CpG probe cg00042837 was strongly associated with TNSM, the fractions of C!A mutations, C!T mutations, and transversions. Each point represents
one sample. The blue line was generated by “lowess,” a nonparametric statistical procedure for nonlinear regression. (C) The enrichment fold change of
CpG probes mapping to different categories in the association with somatic point mutation types. “CGI” represents CpG island regions; “NonCGI”
includes shore and shelf regions. (D) The enrichment fold change of CpG probes mapping to different gene regions in the association with point somatic
mutation types. (E) and (F) show The proportion of identified CpG probes showing positive associations with different somatic point mutation types.
doi:10.1371/journal.pmed.1002162.g003
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(p< 2.5×10−50, Fisher’s exact test): 13.2% of subclonal mutations and 8.0% of clonal mutations
were APOBECmutations. FSM did not differ significantly between synonymous and nonsynon-
ymous mutations (p = 0.98, Fisher’s exact test). FSM differed significantly betweenC!Amuta-
tions and C!Tmutations (p = 2.85×10−27, Fisher’s exact test).
Fig 4D reports the FSM for all patients. FSM did not show significant association with
smoking behaviors (p = 0.59 for smoking status, p = 0.56 for duration, and p = 0.97 for ciga-
rettes per day), neoadjuvant chemotherapy (p = 0.78), or disease stage (p = 0.28). Although not
significant,more advanced patients showed a higher FSM (average FSM: 49.6% for stage I,
55.9% for stage II, and 56.7% for stage III) (Fig 4E).
Mutual Exclusivity Analysis
Mutual exclusivity analysis investigates the relationship between driver genes and identifies
pathways or gene sets that may exert similar oncogenic functions. To increase the statistical
power, we pooledWES data from three LUAD studies: TCGA, Broad Institute, and EAGLE,
Fig 4. Clonal and subclonal point mutations in EAGLE data. Mutations in amplification regions were not included in the analysis.
(A) The number of clonal and subclonal mutations in 37 driver genes for lung adenocarcinoma. (B) Fraction of clonal and subclonal
mutations in each of the nine point mutation types. (C) The fraction of APOBEC-mediated mutations significantly differed in clonal and
subclonal mutations. (D) Estimated fraction of subclonal mutations for each sample. (E) Estimated fractions of subclonal mutations for
patients at different tumor stages.
doi:10.1371/journal.pmed.1002162.g004
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totaling 825 subjects. The analysis was performed for nonsynonymous mutations of 32 signifi-
cantly mutated genes with mutation frequencies greater than 2% usingMEGSA [24]. All
reported p-values were adjusted for multiple comparison using 10,000 permutations.We
identified four significant but overlapping MEGS, with EGFR included in three. The largest
and most significantMEGS (p< 10−4) had 6 genes (BRAF, EGFR,KRAS,MET,NF1, and
ZKSCAN1), with mutations covering 60.3% of patients (Fig 5A). This largely overlapped with
the previously reportedMEGS (BRAF, EGFR,KRAS,MET,NF1, ERBB2, ROS1/ALK/RET,
MAP2K1/HRAS/NRAS) that was discovered by using point mutations, fusions, and amplifica-
tion events [4]. Importantly, ZKSCAN1 is a novel candidate gene identified in our study.
Another highly significantMEGS involving EGFR is (EGFR, STK11,U2AF1, ERBB2), with
mutations in 33.3% of LUAD (Fig 5B). The other twoMEGS were pairwise: (KRAS, TP53),
with mutations covering 69.5% patients, and (EGFR,KEAP), with mutations covering 30.3%
patients. We also performed analysis using mutex [25] to search for specialMEGS with genes
sharing a common downstream target. This analysis identified (EGFR,KRAS, SMARCA4) as a
significantMEGS, with a common downstream target gene PIK3CD.
Gene Fusions in Transcriptome Sequencing
We sequenced the transcriptome of 80 mRNA samples and one Japanese LUAD mRNA sam-
ple previously reported with a KIF5B-RET fusion [11] as a positive control. Using defuse [18],
we successfully detected the KIF5B-RET fusion and identified 49 fusions with both breaking
points located in exonic regions of two different chromosomes or with breaking points less
than 100 kb on the same chromosome (S5 Table). Twenty-four subjects had at least 1 fusion.
We selected 11 fusions with primers available for experimental validation and successfully vali-
dated 10 (S5 Table).
The number of fusions was significantly associated with sex (p = 0.023; females had 0.51
more fusions than males on average) but not significantly associated with age at diagnosis,
smoking behaviors, or disease stage. Consistent with a previous report [31], the number of
fusion events was suggestively associated with reduced survival (p = 0.069) after adjusting for
disease stage, age, and sex. S4–S6 Figs reports three experimentally validated fusions as exam-
ples: FOXK2-KRT20, FOXN1-BLMH, and RUNX1-FARS2.
Fig 5. Mutual exclusivity of driver genes detected in 825 patients combining TCGA, Broad Institute, and EAGLE WES of lung
adenocarcinoma. (A) A MEGS with six genes covering 60.3% of patients. Samples without nonsynonymous mutations in these six
genes are not shown. Samples labelled as blue carry a nonsynonymous mutation in the gene region, while samples labelled as gray do
not carry a synonymous mutation in the gene region. (B) A MEGS with four genes covering 33.3% of patients. Samples without
nonsynonymous mutations in these four genes are not shown.
doi:10.1371/journal.pmed.1002162.g005
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Associations between Genomic Alterations and Clinical Outcomes
We analyzed the association between genomic alterations and clinical outcomes, including sur-
vival, spirometry-basedCOPD, tumor grade, distant metastasis [2], and local relapse after sur-
gery in the EAGLE study. The examined genomic alterations included TNSM, fraction of
transversions, fractions of nine types of point mutations, fractions of the genome covered by
CNAs, and mutational status of TP53 and KRAS, which were most frequently mutated in LUAD.
The associations were evaluated in 93 samples without presurgical neoadjuvant chemotherapy
and were adjusted for sex, age, and disease stage.We tested 70 (= 5 traits × 14 genomic features)
hypotheses and identified statistically significant associations by controlling for an FDR<5%.
The mutational status of TP53 (p = 0.015) and KRAS (p = 0.046) was associatedwith the risk
of developing distant metastasis (Fig 6A). Further adjustment for smoking status and intensity
slightly improved significance:p = 0.014 for TP53 and p = 0.015 for KRAS. The risk of developing
distant metastasis was significantly associated with TNSM (p = 0.0039), the fraction of transver-
sions (p = 0.00055), and the fractions of threemutation types (p = 0.006 for A!G; p = 0.0017 for
C!A; p = 0.0034 for C!T) (Fig 6B). These associations remained significant after further
adjusting for smoking status and intensity: p = 0.0039 for TNSM, p = 0.0016 for the fraction of
transversions, p = 0.0017 for the fraction of A!Gmutations, p = 0.0027 for the fraction of C!A
mutations, and p = 0.010 for the fraction of C!Tmutations. The fraction of APOBEC-mediated
mutations was not significantly associatedwith risk of developingmetastasis (p = 0.49). The
mutation status of POU4F2 or ZKSCAN1was not significantly associated with clinical outcomes.
While TNSMwas significantly associatedwith an increased risk of developing distant metas-
tasis, such an associationwas not significant (p = 0.33) if restricted to the number of mutations in
the LUAD genes summarized in Fig 1B. Restricting to nonsynonymous mutations decreased the
significanceof these associations. This suggests that both synonymous and nonsynonymous
mutations in unidentified “driver” genes could contribute to the risk of developingmetastasis.
Fig 6. Association between genomic features and clinical outcomes. (A) The mutational status of TP53 and KRAS and the time of
developing distant metastasis. p-values were two-sided. Red: mutated; blue: not mutated. (B) The association between the fraction of nine
point mutation types and overall transversions and the time of developing distant metastasis after initial diagnosis. Relative risks and their 95%
confidence intervals were estimated based on a Cox regression model adjusted for age, sex, and disease stage. p-values were two-sided. (C)
Cancer-free survival was not associated with the mutational status of TP53 or KRAS. p-values were two-sided. Red: mutated; blue: not
mutated.
doi:10.1371/journal.pmed.1002162.g006
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We reexamined the associations separately for clonal and subclonal mutations and did not
detect additional significant associations. In fact, restricting to clonal or subclonal mutations
reduced the associations for the risk of developing distant metastasis, suggesting that both
clonal and subclonal mutations contributed to metastatic disease.
No genomic feature was significantly associated with survival. Previous studies reported
that TP53 or U2AF1mutation events were significantly associated with reduced survival [7,32].
We could not evaluate the association of U2AF1 because only one patient in EAGLE carried a
mutation in that gene. Our data did not support the association for TP53 (p = 0.25) (Fig 6C),
possibly because of limited statistical power due to a small sample size. A network smoothing
method [33] was recently proposed to stratify tumors based on somatic mutations and identi-
fied clusters showing significantly different survival in the TCGA data. However, this analysis
did not produce clusters with differential survival distribution in our data. No significant asso-
ciations were detected for COPD, local relapse, or tumor grade.
Discussion
Sequencing Analysis Identified Novel Driver Genes
As expected,we found a high rate of somatic mutations in lung adenocarcinoma (LUAD). More-
over, C!A and the overall transversion ratio were associatedwith smoking phenotypes.We
identified three novel driver genes on the basis of frequency and types of mutations in POU4F2,
ZKSCAN1, and ASEF, and the apparently significant occurrenceof POU4F2 and ZKSCAN1
mutations in LUAD was replicated in a pooled analysis of TCGA and Broad Institute WES stud-
ies. By sequencing additional LUAD samples from the same Italian population, we found no evi-
dence that the mutation frequencies of the three genes differ between populations.
POU4F2 is overexpressed in breast cancer and neuroblastoma cells, in which it promotes
tumor growth [34,35]. In breast cancer, POU4F2 can repress BRCA1 expression [36] and inter-
act with estrogen receptor alpha to enhance its activity [35]. POU4F2 can also induce the
expression of CCD1 and CDK4 in the context of proliferation and cell cycle progression
[34,37], confer migratory and multidrug resistance properties to breast cancer in in vivo mod-
els [38], and cooperate with TP53 to increase transcription of pro-apoptotic genes [39]. Impor-
tantly, growth factors like the epidermal growth factor (EGF) can stimulate the activity of the
POU4F2 promoter and subsequently its mRNA and protein expression, which in turn can
affect POU4F2 target genes influencing growth and behavior of cancer cells.
ZKSCAN1 (or ZNF139) has been reported to have increased expression in gastric cancer
cells [40–43]. In gastric cell lines, it has also been shown to promote migration, invasion, and
multidrug resistance [41,42]. Knockdown of ZKSCAN1 in GC cell lines leads to changes in
expression ofMMP2,MMP9, ICAM1, and TIMP1, impacting cell adhesion and matrix metal-
loprotease activities [42]. BCL-2 and other modulators of apoptosis are also among the
ZKSCAN1 targets [41]. We identifiedZNSCAN1 among a set of genes that are mutually exclu-
sively mutated in lung adenocarcinoma and are all involved in the RTK/RAS/RAF pathway,
including EGFR, BRAF,KRAS,MET, and NF1. This suggests that ZKSCAN1, like the other
genes in this pathway, has an important role in lung carcinogenesis.
Strong Association between DNA Methylation and Somatic Mutation
Signatures
We found a strong association betweenCpG methylation probes and somatic mutations, with
over 1,000 CpG probes associated with C!A transversions within or outside CpG island
regions and over 2,000 CPG probes associated with C!Tmutations outside the CpG island
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regions. An elevated rate of somatic mutations has been observed in hypermethylated tumors
in other cancer types [44]. In our study, the CpG probes mapping to open-sea and intergenic
regions were strongly enriched for the associations with almost all investigated mutation types,
but the largest positive association across all gene regions was with C!Tmutations. In con-
trast, the small proportion of methylated CpG probes mapping to CpG islands were positively
associated with both C!A and C!Tmutations, suggesting a different function of methylation
across point mutation types.
Multiple mechanisms could operate at methylated CpG sequences to produce mutational
hotspots. The most well-known pathway involves spontaneous deamination of 5-methylcyto-
sine to form thymine as T/Gmismatches. If not repaired, mostly by thymine DNA glycosylase
(TDG) or methyl-CpG binding domain protein (MBD4), these mismatches may induce C!T
transition mutations by polymerase bypass [45]. Unmethylated cytosine can also undergo
deamination with subsequent formation of uracil, which is typically rapidly removed by the
ubiquitous uracil-DNA glycosylase enzymes but also by TDG and MBD4. TDG and MBD4
may thus counteract the mutagenic consequences of deamination of cytosine or 5-methylcyto-
sine [46–48] and may also repair oxidized and adducted pyrimidines.We tested whether the
expression of TDG orMBD4was associated with the frequency of C!T transitions in TCGA
LUAD. We found that expression was negatively correlated with C!Tmutations, particularly
for TDG (r = –0.26, p = 10−7), supporting a role for inefficientDNA repair in the etiology of
the observedC!Tmutations. Another pathway, in the presence of 5-methlcytosine at CpG
sequences, involves the formation of DNA adducts at the neighboring guanines. DNA adducts
are typically associated with polycyclic aromatic hydrocarbons (like benzo[a]pyrene) contained
in tobacco smoke. These adducts preferentially induce G to T transversions in the nontranscribed
strand (corresponding to C!A transversion on the other strand) at mCpG sequences. In fact, a
mutation signature enrichedwith C!Amutations has been observed in several tobacco smok-
ing-associated tumors [49]. Previous studies based on mutations in the TP53 gene have shown
that CpGmethylation strongly enhances activated benzo[a]pyrene adduct formation [50,51],
suggesting that CpG dinucleotides represent preferential targets for exogenous chemical carcino-
gens. Additional pathways are likely responsible for the link betweenmethylation and somatic
mutations we observed, and it is also possible that the mutations directly or indirectly induce
methylation changes [52]. Further study is required to explore thesemechanisms, whichmay
suggest strategies to delay or reduce the somatic mutation burden.
Subclonal Mutations and Specific Mutation Signatures Are Associated
with Clinical Outcomes
The majority of mutations we identifiedwere subclonal. However, there was large variability
across subjects in the fraction of lung tumors’ subclonal mutations. Subclonal mutations were
less represented in known driver genes and tended to increase with cancer stage. Notably,
APOBEC-related mutations were strongly enriched in subclonal mutations.
We found a striking association betweenTNSM, specificmutation signatures, and propen-
sity to develop metastasis after the initial lung cancer diagnosis. The risk for metastasis was
associated with both synonymous and nonsynonymous mutations and with clonal and subclo-
nal mutations; notably, it also involved new genes not identified as drivers in the TCGA set.
This implies that additional adenocarcinomas should be sequenced to identify novel driver
genes involved in tumor progression and generate a comprehensive mutation catalog. Interest-
ingly, while the transition mutations C!T and A!G were positively associated with risk of
metastasis, the smoking-related C!Amutations and overall transversion ratio were inversely
associated.Moreover, like APOBEC-related signatures, C!T transitions were also more
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frequent in subclonal mutations [49]. Previous studies exploring lung cancer intratumor het-
erogeneity [53] or the timing of mutational processes [30] suggested that smoking-related
mutations were more clonal, early events in lung cancer evolution, while APOBEC-related
mutations were late events. Another study showed that lung tumor subclonal mutations were
higher in patients (n = 3) with relapsed disease [54]. Subclonal mutations were also reported to
be associated with reduced survival for leukemia [22]. Based on these observations,mutations
developed through endogenous processes—such as C!Tmutations because of spontaneous
deamination and/or inefficient repair (e.g., TDG-related) and APOBEC-mediatedmutations—
appear to impact tumor progression through subclonal branching or risk of metastasis, while
mutations related to exogenous processes—like C!A and other transversion mutations—alter
and dominate the tumor landscape mostly at the beginning of tumor evolution but do not sub-
stantially contribute to tumor progression. Larger integrative studies across stage groups and
using paired primary–metastatic tumor samples are required to further dissect the evolutionary
features of lung cancer.
Strengths and Limitations
Our primary analyses were conducted within the EAGLE study. Subjects’ selection criteria and
modality for enrollment; sample collection and storage; in-person interview for epidemiologi-
cal variables; clinical follow-up of all lung cancer cases; pathology evaluation; quality control;
data management; and laboratory and statistical analyses were all conducted within a single
study, following the same standard operating procedures consistently for all subjects. Lung
cancer cases were all consecutively enrolled from a set of modern hospitals examining over
80% of the patients in the study catchment area within the Lombardy region of Italy, where
over 9 million people are served by a network of health serviceswith universal coverage. These
rigorous procedures ensure that sources of bias are limited and allow the assembly of consistent
and reproducible results representative of all lung adenocarcinoma cases.
Our study had several limitations. First, our study had a small sample size, which limited
the statistical power for studying associations in subgroups of clinical or genomic features. Sec-
ond, the analysis relied on single tumor samples to investigate the subclonality of somatic
mutations and thus could not examine intratumor heterogeneity. Third, not all tumor samples
had transcriptome sequencing data because some tumor samples had a limited amount of
good quality RNA.
In conclusion, this multidimensional analysis of genomic, clonal evolution, and clinical
characteristics of lung adenocarcinoma revealed novel driver genes, epigenome and genome
relationships, and specific links betweenmutation signatures and clinical outcomes. These data
may serve as a foundation for development of more effective forms of treatment for lung
adenocarcinoma.
Supporting Information
S1 Fig. Copy number alteration (CNA) segmentation, purity estimate, and subclonality
analysis. (A) Log R ratio (LRR) and B allele frequency (BAF) data for one tumor sample, pro-
filed using Illumina OmniExpress SNP array. Segmentationwas based on BAF using Nexus.
Copy number status (LOH, deletion, and amplification) was determined by comparing the
sequencing read depth of the tumor DNA to the matched germlineDNA, adjusting for total
sequencing read depth. Red segments represent deletions; green segments represent amplifica-
tions; blue segments represent LOH. (B) For SNP probes in each deletion or LOH, we made a
histogram of BAFs and estimated two peaks (μ1,μ2) using the expectation–maximization (EM)
algorithm. The proportion (π) of cells carrying the CNA was estimated based on (μ1,μ2). After
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estimating π for all deletions and LOHs, we estimated the density of π using nonparametric sta-
tistical methods. Each peak represents one clone. The rightmost clone was determined to be
the primary clone, and others were determined as subclones. (C) Orange: subclonal deletions;
red: clonal deletions; blue: clonal LOH; purple: subclonal LOH.
(TIF)
S2 Fig. A statistical testing framework for determining whether a point mutation was
clonal or subclonal after adjusting for CNA status and subclonality status. (A) In the mixed
DNA, the tumor (denoted as T) DNA accounts for α proportion, and the germline DNA
(denoted as N) accounts for 1 − α proportion. The germline genotype is “AA.” Under the null
hypothesis that the mutation A!B is clonal, the point mutation should happen before the
CNA (deletion) event. We assume that in the tumor DNA, β proportion of tumor cells have a
hemizygous deletion (wild-type allele A is deleted). Then, the mutant allele fraction is calcu-
lated as 2/(2 − αβ). (B) The calculation of the fraction of mutant allele when β proportion of
tumor cells has a LOH event (and the mutant allele B is duplicated). (C) The distribution of p-
values for testing whether a point mutation is clonal. A small p-value supports that the muta-
tion is subclonal. The left panel is for mutations located in LOH regions. The middle panel is
for mutations located in genomic regions without CNA events. The right panel is for mutations
in genomic regions with hemizygous deletions.
(TIF)
S3 Fig. The figures show the significant genomic regions (FDR q-value<0.05) with focal
deletions or amplifications.The figures were produced by GISTIC 2.0.
(TIF)
S4 Fig. An experimentallyvalidated gene fusion between FOXK2 and KRT20.
(TIF)
S5 Fig. An experimentallyvalidated gene fusion between FOXN1 and BLMH.
(TIF)
S6 Fig. An experimentallyvalidated gene fusion betweenRUNX1 and FARS2 located on
two different chromosomes.
(TIF)
S1 Table. All point somatic mutations identified in the EAGLE study.
(XLS)
S2 Table. Associations between somatic mutation signatures and smoking, stage, and pre-
surgery chemotherapy.
(XLS)
S3 Table. Somatic mutations in POU4F2, ZKSCAN1, and ASEF in TCGA, EAGLE, and
Broad Institute studies.
(XLS)
S4 Table. Significant regions with copy number alterations, identified by GISTIC 2.0.
(XLSX)
S5 Table. Fusion events identified in the EAGLE study.
(XLS)
S1 Text. Estimate tumor purity using B allele frequency information in SNP arrays.
(DOCX)
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S2 Text. A statistical approach for determining whether a mutation is clonal or subclonal.
(DOCX)
S3 Text. ASEF protein structure and themutations with functional relevance.
(DOC)
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